Introduction to Europe EV (Extracellular vesicles)-Based Liquid Biopsy Market
The Europe EV-based liquid biopsy market was valued at $18.88 million in 2022 and is anticipated to reach $115.34 million by 2032, witnessing a CAGR of 20.30% during the forecast period 2023-2032. The Europe EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

Market introduction
The use of EV-based liquid biopsy, that offers many advantages over conventional biopsy techniques, has transformed the diagnosis and monitoring of disease. The field of healthcare diagnostics has been revolutionized by its non-invasiveness, real-time monitoring capabilities, and potential for early disease diagnosis. EV-based liquid biopsy has improved patient outcomes, decreased expenses associated with healthcare, and provided a less intrusive and more accessible means of monitoring and diagnosing diseases, including cancer. Furthermore, the market expansion is anticipated to be aided by the entry of many established companies, including Bio-Techne Corporation, QIAGEN N.V., and Thermo Fisher Scientific Inc.

In addition, the market expansion for EV-based liquid biopsies has created economic opportunities, prompted industrial participants to collaborate with academic institutions, and sparked research and development efforts.

Market Segmentation

Segmentation 1: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe"


How can this report add value to an organization?
Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of EVs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.

Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Abcam plc
  • Qiagen N.V.
  • Malvern Panalytical Ltd
  • Lonza Group AG


This report will be delivered in 3-5 working days.